ALLMedicine™ Hyperviscosity Syndrome Center
Research & Reviews 64 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128329
Clinical and Experimental Medicine; Al-Kuraishy HM, Al-Gareeb AI et. al.
May 25th, 2022 - Hyperviscosity syndrome (HVS) recently emerged as a complication of coronavirus disease 2019 (COVID-19) and COVID-19 vaccines. Therefore, the objectives of this critical review are to establish the association between COVID-19 and COVID-19 vaccine...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966494
BMJ Case Reports; Avelino AR, Elmanaseer O et. al.
Mar 31st, 2022 - We describe the case of a man in his 60s with squamous cell carcinoma of the lung with brain metastasis treated with pembrolizumab who subsequently developed T-cell prolymphocytic leukaemia. He was transferred to our hospital with worsening dyspno...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960698
Clinical and Experimental Medicine; Dammacco F, Lauletta G et. al.
Mar 30th, 2022 - Immunoglobulins that reversibly precipitate at temperatures below 37 °C are called cryoglobulins (CGs). Cryoglobulinemia often manifests as cryoglobulinemic vasculitis (CV), whose symptoms range in severity from purpuric eruptions to life-threaten...
https://clinicaltrials.gov/ct2/show/NCT05251896
Feb 23rd, 2022 - Multiple myeloma (MM) is the second most common hematological tumor after non-Hodgkin's lymphoma. The tumor cells originate from plasma cells in the blood pulp and are classified as plasma cells blood myeloma plasmacytomas by the WHO Tumor. It is ...
http://emedicine.medscape.com/article/207097-overview
Feb 3rd, 2022 - Practice Essentials Waldenström macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. [1, 2] It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M ...
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT05251896
Feb 23rd, 2022 - Multiple myeloma (MM) is the second most common hematological tumor after non-Hodgkin's lymphoma. The tumor cells originate from plasma cells in the blood pulp and are classified as plasma cells blood myeloma plasmacytomas by the WHO Tumor. It is ...
https://clinicaltrials.gov/ct2/show/NCT04898647
May 24th, 2021 - Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. Clinical manifestations of the hyperviscosity syndrome (HVS) are related to the large ...
News 3 results
https://www.medscape.com/viewarticle/944772
Feb 5th, 2021 - This transcript has been edited for clarity. Matthew F. Watto, MD: I am Dr Frank Watto, and that is Dr Stuart K. Brigham. With us is our good friend, Dr Paul Nelson Williams. Paul N. Williams, MD: This time around we are going to talk about our ep...
https://reference.medscape.com/viewarticle/944100
Feb 1st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...
https://www.mdedge.com/hematologynews/nhlhub/article/152579/indolent-lymphoma/mayo-experts-outline-waldenstrom
Mary Ellen Schneider
Nov 21st, 2017 - Four to six cycles of bendamustine/rituximab is the primary regimen of choice for symptomatic, treatment-naive patients with Waldenström macroglobulinemia, especially when rapid control is needed for bulky disease, according to treatment guideline.